SPOTLIGHT: Novartis: No more deals, no Roche sale


Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for more deals? And might Novartis offload its one-third stake in Roche to pay for Alcon or some other acquisition. CEO Daniel Vasella (photo) answers both: No. Report | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.